A Three-part Study to Determine the Safety, Tolerability and Pharmacokinetics of GSK1322322 in Healthy Volunteers and Healthy Male Japanese Subjects

PHASE1

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped Emerging GSK1322322 pre-clinical data ID'd potentially reactive metabolites previously not seen that changed the risk: benefit profile and led to a termination

Conditions

Infections, Bacterial

Interventions

DRUG: GSK1322322 Initial fit for purpose tablets
DRUG: GSK1322322 over granulated tablets
DRUG: GSK1322322 intended commercial tablets
DRUG: Placebo tablets
DRUG: 13C-GSK1322322 stable isotope powder
DRUG: GSK1322322 for injection
DRUG: Placebo injection

Sponsor

GlaxoSmithKline